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MALDI MS profiling, using easily available body fluids such as blood serum, has attracted 
considerable interest for its potential in clinical applications.  Despite the numerous reports on MALDI 
MS profiling of human serum there is only scarce information on the identity of the species making up 
these profiles, particularly in the mass range of larger peptides.  Here we provide a list of more than 90 
entries of MALDI MS profile peak identities up to 10 kDa obtained from human blood serum.  Various 
modifications such as phosphorylation were detected amongst the peptide identifications.  The overlap 
with the few other MALDI MS peak lists published so far was found to be limited and hence our list 
significantly extends the number of identified peaks commonly found in MALDI MS profiling of 
human blood serum.  
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There has been great interest in exploiting simple MALDI MS profiling for the analysis of crude or 
little purified human serum or plasma samples for clinical diagnostics [1, 2].  However, it has become 
apparent that there are far more challenges related to its applicability to disease diagnosis than initially 
thought.  The experimental bias and the sensitivity and diagnostic accuracy of MALDI MS profiling 
are of major concern [3, 4].  These are further aggravated by the wide range of abundances and the 
complexity of the endogenous molecular components in blood [2].  However, there have been now 
further reports substantiating the claim that MALDI MS profiling can indeed be a tool for disease 
(outcome) classification [5] and biomarker discovery [6]. 
The fact that little is known about most of these potential biomarkers presents a serious limitation for 
quantification and validation of potentially discriminatory peaks and restricts biomarker assay 
development, including immunoassays that might potentially overcome some of the above analytical 
limitations of MALDI MS profiling. 
Unlike the in-depth analyses of human blood serum or plasma where many hundreds of peptides and 
proteins have been identified [7, 8], MALDI MS profiling focuses on the reproducible, rapid and 
inexpensive acquisition of MS peak patterns that can be used for discriminative analysis as needed in 
population screening or clinical triage. 
Employing MALDI, peptide sequencing is more challenging and usually less sensitive and informative 
for identification purposes than ESI-LC-MS/MS which is mostly combined with extensive pre-
fractionation but without any relation to MALDI MS profiles [9, 10].  Indeed, only a few 
identifications of MALDI MS profile peaks have been reported so far.  The most comprehensive list of 
peptide identifications obtained from human blood serum was reported by Villanueva et al. [11], 
although it provides only peak identifications below 4 kDa.  For blood plasma, Koomen et al. [12] 
reported a list of 249 sequenced plasma profile peptides with a maximum mass of 5.2 kDa. 
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In the present study, we used serum blood samples from healthy persons recruited as part of the United 
Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and United Kingdom Ovarian 
Cancer Population Study (UKOPS) (for details, see [13]).  Polypeptides were enriched from 5 µL of 
serum using a one-step protocol based on reversed phase pre-packed C18-ZipTips®.  The eluates from 
this one-step preparation were used for this study.  The acquired MS/MS data are available in the 
PRIDE database (Experiment Accession # 11692-11694).  Details on the materials and methods 
employed can be found in Supplemental Data 1. 
MALDI-TOF MS profiling of 60 serum samples revealed 108 aligned peaks within the combined 
UKCTOCS and UKOPS serum sample set, using an S/N ratio above 5 (Supplemental Data 2, A) and 
156 peaks at S/N>3.  Despite the high number of common peaks, the different sample collection and 
handling protocols for the UKOPS and UKCTOCS sample sets resulted in markedly different MALDI 
MS profiles and peak intensities (Figure 1).  Thus, sera from both sample sets were employed to 
identify as many profile peaks as possible using the higher mass accuracy and sequencing capability of 
MALDI Q-TOF instrumentation. 
Many of the peak identifications were obtained by direct switching from MALDI MS to MALDI CID 
MS/MS as described in Supplemental Data 1, analysing the precursor ions determined in the MALDI 
MS profile.  This approach provided a total of 36 identities through searching the human subset of the 
NCBInr protein database using MASCOT with an average mass accuracy of the precursor ion mass 
measurements of 13 ppm (Supplemental Data 2, B).  The next approach was using the same samples 
for nanoESI MS/MS analysis, using the chip-based Nanomate system.  Similarly to the MALDI 
analysis, MS profile spectra were first acquired and MS/MS analysis of the precursor ions of the MS 
profile provided their identity.  In this approach, the MALDI and ESI MS profiles were compared to 
match peaks unambiguously and a total of 16 peaks were identified, of which 6 could not be identified 
by earlier MALDI MS/MS analysis. 
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Next, the serum sample eluates were fractionated by off-line C18 reversed-phase chromatography and 
the fractions were analysed by chip-based nanoESI as before.  In contrast to many previous reports 
using major-protein depletion or multi-dimensional separation strategies where 200-400 peptides were 
identified [9, 10, 12], the objective of our fractionation strategy was to enhance the identification of 
peptides but to ensure that the obtained identities are the correct identities of the MALDI MS profile 
peaks.  In all large-scale serum proteomic studies published so far this has not been achieved and can 
therefore result in a high false positive rate.  Thus, we also monitored the change of the MALDI MS 
profile after fractionation by comparing the pre-fractionation MALDI MS profile with the MALDI MS 
(and ESI MS) profiles of each fraction.  The fractions were then analysed by chip-based nanoESI 
MS/MS and MASCOT searching of the MS/MS data resulted in an additional 28 identities and another 
9 confirmations of identities obtained by the two earlier approaches without LC fractionation. 
As expected for peaks above m/z 4,500, none of these approaches led to unambiguous peptide 
identification.  The collected LC fractions were therefore digested with trypsin and analysed by chip-
based nanoESI MS/MS.  For each fraction, the protein hits from these MASCOT searches were then 
used to search peptide profile peaks from the undigested fractions for sequence mass matches within a 
mass tolerance of 50 ppm.  Any putative matches were further interrogated by their isotopomer 
distribution, their known post-translational modifications and the likelihood of occurrence derived from 
their structural and functional information in protein databases.  Where possible, fragment ion spectra 
from the previous methods were also used to substantiate putative identities.  Overall, this approach led 
to an additional 11 peak identities. 
In total, more than 80 polypeptides were identified with high confidence, representing peptides from 13 
different but highly abundant proteins (see Supplemental Data 2, B).  Among these there were three full 
length proteins, Apoliprotein CII (Apo CII), Apolipoprotein CIII (Apo CIII) and Connective tissue-
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activating peptide III (CTAP-III).  The peaks at m/z 1547 and 1616 were clearly identified by both 
MALDI MS/MS and ESI MS/MS without LC fractionation, and correspond to Fibrinopeptide A 
fragments phosphorylated at serine (see Supplemental Data 3, (a)-(d)).  Interestingly, many of the 
Fibrinopeptide A/B peaks and others show a loss of 17 Da (ammonia) and sometimes of water.  Some 
of the identified peptides/proteins were found to be oxidised and they were excluded from the list since 
many of them did not appear in the MALDI MS profiles and were most likely products obtained from 
the sample handling.  This clearly shows that the MS peaks/profiles can substantially change with 
complex sample preparation methods, underlining the need for careful profile peak identification that is 
different to peptide identification of in-depth proteomic serum analyses. 
A detailed comparison of our peak list with the peak lists reported by Villanueva et al. [11] and Peng et 
al. [14] shows that the lists are complementary rather than redundant (see Figure 2 and Table 1).  It is 
worth noting that although the number of identified peaks from this study is comparable to the number 
reported by Villaneuva et al. [11], only about 30% (25 peaks) are common between the two lists 
(Figure 2).  Furthermore, the present study was able to identify nine polypeptides in the mass range of 
4–10 kDa.  However, within this mass range there were many more polypeptides for which the parent 
protein was identified after digestion but the data was inconclusive for assigning single identities to the 
MALDI MS profile peaks. 
A comparison with a list of plasma peptide identifications reported by Koomen et al. [12] shows that 
again only about 25 peaks are common (about 10% of the 249 peptide identifications), reflecting the 
inherent difference between blood plasma and serum. 
Combining this peak list with the lists from Villanueva et al. [11] and Peng et al. [14] increases the 
number of identified polypeptides of MALDI MS serum profiles to 139 (Table 1).  This provides an 
extensive list of peptide identifications obtained from human blood serum that can be used for 
7 
 
provisional identification of MALDI MS profiling peaks below 10 kDa through simple comparison.  
Furthermore, this will allow, by quick comparison of MS profile and/or MS/MS data, the identification 
of many potential biomarkers commonly listed in reports without identification and thus facilitate 
biomarker validation.  
The analysis of some of the MALDI MS profiling peaks resulted in MS/MS spectra different to those 
usually found for peptides (Supplemental Data 3, (e)-(f)).  These fragmentation spectra were typical for 
phospholipids and their identification was carried out by comparing their accurate masses (within 10 
ppm) to the calculated masses obtained from the LipidMaps database (www.lipidmaps.org).  The 
presence of ion fragments at m/z 86.10, 104.11 and 184.07 in all MS/MS spectra is characteristic for 
choline, H2O-choline and phosphocholine, respectively (see Supplemental Data 3, (e)-(f), and 
Supplemental Data 2, C), and confirmed that these peaks are derived from phosphocholine lipids. 
Interestingly, a comparison with a recently published list of endogenous serum peptides that were 
obtained by extensive prefractionation and ESI-MS/MS shows that more than 40% of the fribrinogen 
(P02671) peptides in Table 1 were not identified despite the much higher number of identified peptides 
(>1000) obtained in that study [15].  Other comparisons including lists of endogenous plasma peptides 
[16] and other proteins showed similar results.  In addition, none of these lists include any post-
translational modifications (PTMs), and only recently a few phosphorylated endogenous serum 
peptides were reported [17].  The presented list is based on MALDI MS profile peak identification and 
as such includes PTMs as well as other non-peptidic components.  The focus on MALDI MS profile 
peak identification also provides an additional and decisive advantage.  While other lists might provide 
many more endogenous peptides, these are not linked to MALDI MS profiling.  As a result entries 
cannot be ranked according to their signal intensity in MALDI MS profiles and many of the entries will 
have the same mass value within a given mass tolerance.  For instance, the above comparison (based 
8 
 
only on fibrinogen peptides) reveals that the profile peak at m/z 1518.7 would have been wrongly 
assigned using the more extensive list of endogenous serum peptides published by Bakun et al. [15].  In 
the latter, the peptide at the corresponding mass was identified as NRGDSTFESKSYK (cf. Table 1).  
In the same list, there is no entry for the serine-phosphorylated peptide DSGEGDFLAEGGGV or for 
its associated peptide that has lost phosphoric acid, which has the same mass value as 
NRGDSTFESKSYK within a tolerance of 25ppm.  In addition, the peptide entries for the profile peak 
at m/z 1309.6 would have led to an ambiguous identification of either SSSYSKQFTSST or 
DSGEGDFLAEGGGV, again assuming a mass accuracy of around 25ppm or more.  Even at 10ppm 
most fibrinogen peptides are not unique for their respective mass value.  For instance, there are seven 
fibrinogen peptides with exactly the same m/z value of 1206.57.  The above analysis clearly shows that 
any list of endogenous serum peptides can only be useful for MALDI MS profiling if the peak 
identifications can be directly linked to the MALDI MS profiles. 
In general, a comparison with the published literature shows that this new list of MALDI serum profile 
peak identifications can be highly advantageous.  It can be used for initial putative peak identification, 
particularly where similar strict sample handling procedures have been followed.  Recently published 
MALDI serum profiling work [18] using FT-ICR-MS for the identification of acute leukemia 
biomarker candidate peaks at m/z 1778 and 1865 revealed these peaks to be fragments of complement 
C3f as listed in Table 1.  Other examples can be found for the average m/z 1212, 1350, 1451, 1564, 
1691, 1779, 1866 [19]; 3275 [20]; 1467 [21]; 5905 [22]; and 4283 [23].  Some of these profile peaks 
were even obtained from blood plasma.  Nonetheless, one needs to be aware that the presented dataset 
is based on the analysis of C18-purified but otherwise non-fractionated serum and that its application to 
plasma or fractionated serum MS profile peaks may be limited.  Some of the limitation with respect to 
sample handling can be seen in the comparison with the data from Villanueva et al. and Peng et al. 
(Table 1 and Figure 2).  However, there are many reasons for the low degree of overlap between these 
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three studies.  In our study we identified non-peptidic and larger peptide peaks and used exclusively 
healthy persons while the other two studies either focused on peptide identification of cancer-specific 
profile peaks or used SELDI chips for serum fractionation.  Within our study we tried to extend the 
currently available and biased lists by employing a sample handling protocol that researchers in the 
field consider as best practice and performing peak identification that is not based on disease-specific 
biomarker candidates. 
In conclusion, the presented dataset provides the identification of more than 90 serum MALDI MS 
profiling peaks with little overlap with already published datasets.  The more than 80 identified 
polypeptides originate from only 13 proteins.  Complementary to other published lists this dataset also 
provides the identification of very low molecular weight (< 1 kDa) peaks often associated with 
phospholipids and peaks above 5 kDa.  Together with previously published data the most 
comprehensive MALDI MS serum profiling list consisting of 148 peak identifications is now available 
(see Table 1). 
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Figure 1: 
Averaged MALDI-TOF mass spectra of human serum samples collected for UKCTOCS (upper panel) 
and UKOPS (lower panel) and obtained from purifications of 5μL-aliquots using pre-packed C18 
ZipTips®. Averaged mass spectra were generated by ClinProTools software v2.1 after baseline 
subtraction, smoothing, normalisation and peak realignment. 
Figure 2: 
Venn diagram showing the number of overlapping and total number of peptides identified in this study 
and those of the studies of Villanueva et al. [11] and Peng et al. [14]. 
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Table 1. List of MALDI MS profile peaks 
Calculated 
Monoisot. 
[M+H]+ 
Calculated 
Average 
[M+H]+  
Protein/Peptide or Lipid Peptide Sequences Identified Study 
UniProt 
Entry Name (Fragment) Tiss et al. 
Villanueva et 
al. Peng et al. 
445.2518 445.4944 P02671 FPA (12-16) E.GGGVR √   
496.3426  NA PC(16:0/0:0) NA √   
518.3236  NA PC(18:3/0:0) NA √   
520.3393  NA PC(18:2/0:0) NA √   
522.3590  NA PC(18:1/0:0) NA √   
524.3742  NA PC(18:0/0:0) NA √   
574.2944 574.6087 P02671 FPA (11-16) A.EGGGVR √   
645.3315 645.6867 P02671 FPA (10-16) L.AEGGGVR √   
740.2846 740.7172 P02675 FPB (1-7) – NH3 – H2O Q(-NH3)GVND(-H2O)NE.E √   
758.4155 758.8522 P02671 FPA (9-16) F.LAEGGGVR √ √  
758.5701  NA PC(16:0/18:2 or 18:0/16:2) NA √   
760.5915  NA PC(16:0/18:1 or 18:0/16:1) NA √   
822.4297 822.9731 P10909 Clusterin precursor (217-222) P.HFFFPK.S  √  
842.3944 842.9214 Q14624 ITIH4 (681-687) D.HAAYHPF.R  √  
864.4097 864.9299 P02671 FPA (7-15) D.DFLAEGGGV.R √   
869.3272 869.8334 P02675 FPB (1-8) – NH3 – H2O Q(-NH3)GVND(-H2O)NEE.G √   
904.4676 905.0324 P01042 Bradykinin (1-8) RPPGFSPF.R  √  
905.4839 906.0288 P02671 FPA (8-16) D.FLAEGGGVR √ √  
920.4624 921.0385 P01042 Bradykinin (1-8) [Pro_Hydroxyl] RPPGFSP(Hydroxyl)F.R √ √  
926.3486 926.8856 P02675 FPB (1-9) – NH3 – H2O Q(-NH3)GVND(-H2O)NEEG.F √   
942.4680 943.0358 P01024 Complement C3f fragment (9-16) I.HWESASLL.R  √  
944.3592 944.8817 P02675 FPB (1-9) – NH3 Q(-NH3)GVNDNEEG.F √   
991.6807  NA PC(16:0/0:0) dimer NA √   
998.4955 999.1075 Q14624 ITIH4 (681-688) D.HAAYHPFR.  √  
1015.6831  NA PC(16:0/0:0) + PC(18:2/0:0) dimer NA √   
1020.5108 1021.1174 P02671 FPA (7-16) G.DFLAEGGGVR √ √  
1055.5520 1056.1937 P01024 Complement C3f fragment (8-16) R.IHWESASLL.R  √  
1060.5787 1061.2185 P01042 Bradykinin RPPGFSPFR  √  
1073.4171 1074.0634 P02675 FPB (1-10) – NH3 – H2O Q(-NH3)GVND(-H2O)NEEGF.F √   
1076.5736 1077.2179 P01042 Bradykinin [Pro_Hydroxyl] RPPGFSP(Hydroxyl)FR  √  
1077.5323 1078.1693 P02671 FPA (6-16) E.GDFLAEGGGVR √ √  
1091.4277 1092.0559 P02675 FPB (1-10) – NH3 Q(-NH3)GVNDNEEGF.F √   
1108.4542 1109.1005 P02675 FPB (1-10) QGVNDNEEGF.F √   
1194.5273 1195.2274 P02671 FPA (3-15) D.SGEGDFLAEGGGV.R √   
1206.5749 1207.2848 P02671 FPA (5-16) G.EGDFLAEGGGVR √ √  
1211.6531 1212.3798 P01024 Complement C3f fragment (7-16) H.RIHWESASLL.R  √  
1220.4855 1221.2413 P02675 FPB (1-11) – NH3 – H2O Q(-NH3)GVND(-H2O)NEEGFF.S √   
1238.4961 1239.2519 P02675 FPB (1-11) – NH3 Q(-NH3)GVNDNEEGFF.S √   
1263.5963 1264.3367 P02671 FPA (4-16) S.GEGDFLAEGGGVR √ √  
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1277.7153 1278.5258 P10909 Clusterin precursor (217-226) P.HFFFPKSRIV.R  √  
1309.5542 1310.3160 P02671 FPA (2-15) A.DSGEGDFLAEGGGV.R √   
1325.5281 1326.3076 P02675 FPB (1-12) – NH3 Q(-NH3)GVNDNEEGFFS.A √   
1348.7120 1349.5194 P01024 Complement C3f fragment (6-16) T.HRIHWESASLL.R  √  
1350.6284 1351.4149 P02671 FPA (3-16) D.SGEGDFLAEGGGVR √ √  
1396.5652 1397.4098 P02675 FPB (1-13) – NH3 Q(-NH3)GVNDNEEGFFSA.R √   
1447.6447 1448.4929 P02671 FPA (2-16) – H2O A.DS(-H2O)GEGDFLAEGGGVR √   
1449.7597 1450.6235 P01024 Complement C3f fragment (5-16) I.THRIHWESASLL.R  √  
1465.6554 1466.5035 P02671 FPA (2-16) A.DSGEGDFLAEGGGVR √ √  
1498.7873 1499.6562 P0C0L4 Complement C4-A (1337-1349) R.NGFKSHALQLNNR.Q  √  
1518.6818 1519.5717 P02671 FPA – H2O ADS(-H2O)GEGDFLAEGGGVR √   
1530.8692 1531.8273 Q59FS1 IGIH4 R.RPHFFFPKSRIV.R   √ 
1536.6924 1537.5823 P02671 FPA ADSGEGDFLAEGGGVR √ √  
1542.5939 1543.4566 P02671 FGA chain (605-619) A.DEAGSEADHEGTHST.K  √   
1545.6000 1546.4482 P02671 FPA (2-16) + P A.DSpGEGDFLAEGGGVR √   
1562.8438 1563.7813 P01024 Complement C3f fragment (4-16) K.ITHRIHWESASLL.R  √  
1616.6594 1617.5493 P02671 FPA + P ADSpGEGDFLAEGGGVR √   
1626.8459 1627.7857 P0C0L4 Complement C4-A (1337-1350) R.NGFKSHALQLNNRQ.I  √  
1690.9387 1691.9540 P01024 Complement C3f fragment (3-16) S.KITHRIHWESASLL.R  √  
1739.9299 1740.9619 P0C0L4 Complement C4-A (1337-1351) R.NGFKSHALQLNNRQI.R √ √  
1751.9187 1752.9510 P01024 Complement C3f fragment (1-15) .SSKITHRIHWESASL.L  √  
1762.9222 1763.9653 P0C0L4 Complement C4-A (1353-1368) R.GLEEELQFSLGSKINV.K  √  
1768.8236 1769.8406 P01024 Complement C3 (1322-1337) S.EETKENEGFTVTAEGK.G √   
1771.8497 1772.8893 P06727 Apolipoprotein A-IV (288-303) K.SLAELGGHLDQQVEEF.R  √  
1777.9708 1779.0314 P01024 Complement C3f fragment (2-16) S.SKITHRIHWESASLL.R  √  
1786.8547 1787.9504 Q14624 ITIH4 (671-687) L.GLPGPPDVPDHAAYHPF.R √ √  
1807.9297 1808.9884 P02647 Apolipoprotein A-I (149-163) A.ELQEGARQKLHELQE.K √ √  
1847.8379 1848.8859 P02671 FGA chain (607-624) E.AGSEADHEGTHSTKRGHA.K √   
1855.8555 1856.9375 P01024 Complement C3 (1321-1337) R.SEETKENEGFTVTAEGK.G √   
1865.0028 1866.1295 P01024 Complement C3f fragment (1-16) SSKITHRIHWESASLL.R √ √  
1883.8114 1884.8701 P02671 FGA chain (605-622) A.DEAGSEADHEGTHSTKRG.H  √   
1884.9899 1886.0639 P02671 FGA chain (606-622) D.HEGTHSTKRGHAKSRPV.R   √ 
1896.0311 1897.1494 P0C0L4 Complement C4-A (1336-1351) G.RNGFKSHALQLNNRQI.R √ √ √ 
1927.9508 1929.0755 P06727 Apolipoprotein A-IV (288-304) K.SLAELGGHLDQQVEEFR.R  √  
1943.9080 1945.0261 P01042 HMW Kininogen (440-456) H.NLGHGHKHERDQGHGHQ.R √ √  
1971.0433 1972.2228 P02647 Apolipoprotein A-I (251-267) K.VSFLSALEEYTKKLNTQ  √  
2008.0788 2009.3518 Q0P5N8 TMSB4X (31-47) K.PDMAEIEKFDKSKLKKT.E √   
2010.9708 2012.2352 Q14624 ITIH4 (669-687) – NH3 R.Q(-NH3)LGLPGPPDVPDHAAYHPF.R √   
2021.1039 2022.2950 P01024 Complement C3f fragment SSKITHRIHWESASLLR  √ √ 
2027.9974 2029.2378 Q14624 ITIH4 (669-687) R.QLGLPGPPDVPDHAAYHPF.R  √ √ 
2045.9172 2047.1100 P01042 HMW Kininogen (480-497) L.DDDLEHQGGHVLDHGHKH.K √   
2053.0812 2054.2822 P02647 Apolipoprotein A-I (220-238) K.ATEHLSTLSEKAKPALEDL.R  √  
2067.1921 2068.4016 P02775 Platelet Basic Protein precursor (110-127) D.APRIKKIVQKKLAGDESAD   √ 
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2091.9074 2093.0900 P02671 FGA chain (605-624) A.DEAGSEADHEGTHSTKRGHA.K √   
2113.0771 2114.3166 Q0P5N8 TMSB4X (52-70) E.KNPLPSKETIEQEKQAGES √   
2115.0512 2116.3462 Q14624 (ITIH4) (347-367) R.NVHSAGAAGSRMNFRPGVLSS.R  √  
2122.8618 2124.1563 P02671 FGA chain (600-619) K.SYKMADEAGSEADHEGTHST.K √   
2127.0128 2128.2565 P01042 HMW Kininogen (458-477) R.GHGLGHGHEQQHGLGHGHKF.K  √  
2162.9445 2164.1688 P02671 FGA chain (604-624) M.ADEAGSEADHEGTHSTKRGHA.K √   
2184.0985 2185.4238 Q14624 ITIH4 (669-688) R.QLGLPGPPDVPDHAAYHPFR.R  √  
2209.0619 2210.3192 P01042 HMW Kininogen (438-456) R.KHNLGHGHKHERDQGHGHQ.R  √ √ 
2267.1891 2268.5127 P02649 Apolipoprotein E (212-232) A.TVGSLAGQPLQERAQAWGERL.R  √  
2271.1305 2272.5274 Q14624 ITIH4 (667-687) S.SRQLGLPGPPDVPDHAAYHPF.R √ √ √ 
2279.2718 2280.6046 P02775 Platelet Basic Protein precursor (108-127) D.PDAPRIKKIVQKKLAGDESAD  √ √ 
2305.2034 2306.5524 P0C0L4 Complement C4-A (1353-1374) R.GLEEELQFSLGSKINVKVGGNS.K  √  
2353.1518 2354.5363 Q0P5N8 TMSB4X (50-70) – NH3 T.QEKN(-NH3)PLPSKETIEQEKQAGES √   
2358.1626 2359.5787 Q14624 ITIH4 (666-687) S.SSRQLGLPGPPDVPDHAAYHPF.R  √  
2371.1624 2372.5469 Q0P5N8 TMSB4X (50-70) T.QEKN(deam)PLPSKETIEQEKQAGES √   
2378.2098 2379.6342 P0C0L4 Complement C4-A (1429-1449) K.DDPDAPLQPVTPLQLFEGRRN.R √   
2379.0371 2380.4173 P02671 FGA (577-597) S.SSYSKQFTSSTSYNRGDSTFE.S  √  
2409.2633 2410.6688 P02649 Apolipoprotein E (210-232) R.AATVGSLAGQPLQERAQAWGERL.R  √  
2451.2051 2452.6608 P02766 Transthyretin precursor (101-123) K.ALGISPFHEHAEVVFTANDSGPR.R  √  
2453.9610 2455.4140 Q0P5N8 TMSB4X (49-70) – NH3 E.TQ(-NH3)EKNPLPSKETIEQEKQAGES √   
2464.0793 2465.5698 P02671 FGA chain (600-622) K.SYKMADEAGSEADHEGTHSTKRG.H √   
2471.2260 2472.6679 Q0P5N8 TMSB4X (49-70) E.TQEKNPLPSKETIEQEKQAGES √   
2508.3529 2509.7985 P06727 Apolipoprotein A-IV (256-278) R.ISASAEELRQRLAPLAEDVRGNL.K  √  
2544.2297 2545.6650 P02671 FGA chain (606-629) D.EAGSEADHEGTHSTKRGHAKSRPV.R   √ 
2551.1769 2552.7529 P0C0L4 Complement C4-A (957-979) R.TLEIPGNSDPNMIPDGDFNSYVR.V  √  
2553.1012 2554.5991 P02671 FGA chain (576-598) K.SSSYSKQFTSSTSYNRGDSTFES.K √ √  
2565.3644 2566.8549 P02649 Apolipoprotein E (210-233) R.AATVGSLAGQPLQERAQAWGERLR.A  √  
2567.3729 2568.9088 P02768 Albumin precursor (27-48) A.HKSEVAHRFKDLGEENFKALVL.I √   
2582.3402 2583.9185 Q14624 ITIH4 (617-639) R.NVHSGSTFFKYYLQGAKIPKPEA.S √   
2599.2635 2600.7734 P02647 Apolipoprotein A-IV (280-303) K.GNTEGLQKSLAELGGHLDQQVEEF.R  √  
2602.3107 2603.8204 P00488 Factor XIIIa (14-38) R.AVPPNNSNAAEDDLPTVELQGVVPR.G  √  
2627.3400 2628.9194  Q14624 ITIH4 (663-687) P.GVLSSRQLGLPGPPDVPDHAAYHPF.R  √  
2659.2567 2660.7791 P02671 FGA chain (605-629) A.DEAGSEADHEGTHSTKRGHAKSRPV.R  √ √ √ 
2704.4516 2706.0385 P0C0L4 Complement C4-A (1353-1378) R.GLEEELQFSLGSKINVKVGGNSKGTL.K  √  
2724.3893 2726.0348 Q14624 ITIH4 (662-687) R.PGVLSSRQLGLPGPPDVPDHAAYHPF.R  √  
2753.4369 2755.1053 P02768 Albumin precursor (25-48) R.DAHKSEVAHRFKDLGEENFKALVL.I √   
2755.3646 2756.9595 P06727 Apolipoprotein A-IV (280-304) K.GNTEGLQKSLAELGGHLDQQVEEFR.  √  
2768.2282 2769.8514 P02671 FGA chain (576-600) K.SSSYSKQFTSSTSYNRGDSTFESKS.Y √ √ √ 
2778.4520 2780.0741 P02654 Apolipoprotein C-I (29-53) P.DVSSALDKLKEFGNTLEDKARELIS.R  √  
2816.3234 2817.9581 P02671 FGA (548-574) R.GSESGIFTNTKESSSHHPGIAEFPSRG.K  √  
2829.4112 2831.0626 Q0P5N8 TMSB4X (46-70) K.KTETQEKNPLPSKETIEQEKQAGES √   
2861.3343 2863.6505 P02671 FGA chain (603-629) K.MADEAGSEADHEGTHSTKRGHAKSRPV.R √  √ 
2931.2915 2933.0274 P02671 FGA chain precursor (576-601) K.SSSYSKQFTSSTSYNRGDSTFESKSY.K √ √ √ 
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2989.4292 2991.2246 P02671 FGA chain (602-629) Y.KMADEAGSEADHEGTHSTKRGHAKSRPV.R √   
3156.6265 3158.5491 Q14624 ITIH4 (617-644) R.NVHSGSTFFKYYLQGAKIPKPEASFSPR.R √ √ √ 
3182.7347 3184.6627 P02647 Apolipoprotein A-I (240-267) R.QGLLPVLESFKVSFLSALEEYTKKLNTQ  √  
3190.4270 3192.3659 P02671 FGA (576-603) K.SSSYSKQFTSSTSYNRGDSTFESKSYKM.A  √ √ 
3200.8001 3202.6864 P0C0L4 Complement C4-A (1353-1382) R.GLEEELQFSLGSKINVKVGGNSKGTLKVLR.T  √  
3206.4219 3208.3653 P02671 FGA (576-603) [Met-ox] K.SSSYSKQFTSSTSYNRGDSTFESKSYKMox.A  √  
3239.5246 3241.4788 P02671 FGA chain (600-629) K.SYKMADEAGSEADHEGTHSTKRGHAKSRPV.R √ √ √ 
3261.4641 3263.4440 P02671 FGA chain (576-604) K.SSSYSKQFTSSTSYNRGDSTFESKSYKMA.D √ √ √ 
3272.6422 3274.6954 Q14624 ITIH4 (658-687) R.MNFRPGVLSSRQLGLPGPPDVPDHAAYHPF.R √ √  
3277.4590 3279.4434 P02671 FGA (576-604) [Met-ox] K.SSSYSKQFTSSTSYNRGDSTFESKSYKMoxA.D  √  
3377.7230 3379.7435 P02647 Apolipoprotein A-I (148-176) R.AELQEGARQKLHELQEKLSPLGEEMoxRDRA.R  √  
3675.9075 3678.0877 Q0P5N8 TMSB4X (39-70) K.FDKSKLKKTETQEKNPLPSKETIEQEKQAGES √   
3953.9098 3956.4034 Q14624 ITIH4 (645-681) R.RGWNRQAGAAGSRMNFRPGVLSSRQLGLPGPPDVPDH.A √   
3970.9882 3973.4255 Q14624 ITIH4 (650-687) R.QAGAAGSRMNFRPGVLSSRQLGLPGPPDVPDHAAYHPF.R  √  
4280.1319 4282.7883 Q59FS1 IGIH4 (602-642) R.NVHSAGAAGSRMNFRPGVLSSRQLGLPGPPDVPDHAAYHPF.R √  √ 
4961.3111 4964.3899 P02671 FGA chain (529-574) or (513-558) T.FPGFFSPMLGEFVSETESRGSESGIFTNTKESSSHHPGIAEFPSRG.K  or  
R.HPDEAAFFDTASTGKTFPGFFSPMLGEFVSETESRGSESGIFTNTK.E 
√   
5334.3536 5337.5402 P02671 FGA chain (577-624) K.SSSYSKQFTSSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHA.K √  √ 
5901.7029 5905.2293 P02671 FGA chain (577-629) K.SSSYSKQFTSSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV.R √  √ 
6627.3167 6631.4463 P02655 Apolipoprotein C-II (32-90) M.PSPTFLTQVKESLSSYWESAKTAAQNLYEKTYLPAVDEKLRDLYSKSTAAMSTYTGIFT.D √   
8200.0508 8205.1815 P02655 Apolipoprotein C-II (29-101) Q.DEMPSPTFLTQVKESLSSYWESAKTAAQNLYEKTYLPAVDEKLRDLYSKSTAAMSTYTGIF
TDQVLSVLKGEE 
√   
8760.2248 8765.6732 P02656 Apolipoprotein C-III SEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQARGWVTDGFSSLKDYWSTVKDKFSE
FWDLDPEVRPTSAVAA 
√   
8910.3855 8915.9261 P02655 Apolipoprotein C-II (Chain A) TQQPQQDEMPSPTFLTQVKESLSSYWESAKTAAQNLYEKTYLPAVDEKLRDLYSKSTAAMSTY
TGIFTDQVLSVLKGEE 
√   
9282.8208 9288.7182 P02775 CTAP-III NLAKGKEESLDSDLYAELRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGRKICL
DPDAPRIKKIVQKKLAGDESAD 
√   
* In the MS/MS spectra of these peaks, Choline, H2O-Choline and PhosphoCholine peaks were dominant but no corresponding phospholipids 
were found in the LipidMaps database. 
CTAP-III: Connective tissue-activating peptide III; FGA: Fibrinogen alpha; FPA: Fibrinopeptide A; FPB: Fibrinopeptide B; HMW 
Kininogen: High molecular weight kininogen; IGIH4: Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) varaint; 
ITIH4: Inter-alpha-trypsin inhibitor heavy chain H4; NA: Not applicable; PC: Phophatidylcholine; TMSB4X: Thymosin, beta 4.  [M+H]+ 
values were calculated using IsotopePattern Software (Bruker Daltonics). 
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Synopsis 
Despite the numerous reports on MALDI MS profiling of human serum there is only scarce information on 
the profile peaks’ identities.  Here, we provide a well-characterised list of peak identities obtained from 
human blood serum that can be used for provisional identification of these peaks and show that in-depth 
proteomic analysis of many thousands of peptides by (multidimensional) LC-ESI-MS/MS cannot provide the 
necessary information for identifying MALDI-generated profile peaks. 
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